NextCure, Inc.
corporate_fare Company Profile
NextCure, Inc. (NASDAQ:NXTC) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for NXTC at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-20, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 16 rated 8 or above. Recent SEC coverage for NXTC spans 8-K, 10-Q, S-4/A, 425.
Recent high-impact activity:
- NextCure Sets CVR Record Date of Dec 8 and Distribution Date of Dec 14 for Avere Merger
- NextCure Receives Nasdaq Equity Deficiency Notice; January 4, 2027 Cure Deadline Set
- NextCure 10-Q: $8.7M Cash, Going Concern Warning and Nasdaq Equity Deficiency Ahead of Dec 9 Merger Vote
- NextCure Posts $6.8M Q3 Loss With $8.7M Cash Ahead of December 9 Merger Vote
- Avere Merger Financing Grows to ~$820M With New $500M Placement
Financial Snapshot
Short Interest & Short Volume
2.97 days to coverFINRA reported short interest of 184,029 shares in NXTC as of the October 30, 2026 settlement, a 16.7% decrease from the prior period — about 3.0 days to cover at its recent average daily volume. On November 20, 2026, 11.9% of NXTC volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.